Atea Pharmaceuticals, Inc.

For the period ended Sep 30, 2026. Filed Nov 9, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 9, 2026

AVIR$4.20-4.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · Additional · Accumulated Other · Accumulated · Total
Shares · Amount · Paid-in Capital · Comprehensive Gain (Loss) · Deficit · Stockholders' Equity
Balance—January 1, 2026	78,126,796	$78		$797,751	$174	$(522,569)		$275,434
Issuance of common stock upon vesting of restricted stock units	1,216,262	1		(747)	—	—		(746)
Issuance of common stock under employee stock purchase plan	53,966	—		132	—	—		132
Issuance of common stock upon exercise of stock options	630,075	1		870	—	—		871
Stock-based compensation expense	—	—		3,729	—	—		3,729
Other comprehensive loss	—	—		—	(271)	—		(271)
Net loss	—	—		—	—	(45,440)		(45,440)
Balance—March 31, 2026	80,027,099	80		801,735	(97)	(568,009)		233,709
Issuance of common stock upon vesting of restricted stock units	177,600	—		—	—	—		—
Stock-based compensation expense	—	—		3,381	—	—		3,381
Other comprehensive income	—	—		—	1	—		1
Net loss	—	—		—	—	(32,933)		(32,933)
Balance—June 30, 2026	80,204,699	80		805,116	(96)	(600,942)		204,158
Issuance of common stock under employee stock purchase plan	26,111	—		115	—	—		115
Issuance of common stock upon exercise of stock options	64,274		80				80
Stock-based compensation expense	—	—		3,467	—	—		3,467
Other comprehensive income	—	—		—	23	—		23
Net loss	—	—		—	—	(32,162)		(32,162)
Balance—September 30, 2026	80,295,084	$80		$808,778	$(73)	$(633,104)		$175,681

Common Stock · Additional · Accumulated Other · Accumulated · Total
	Shares	Amount	Paid-in Capital	Comprehensive Gain (Loss)	Deficit	Stockholders' Equity
Balance—January 1, 2025	84,463,059	$84	$802,770	$233	$(364,220)	$438,867
Issuance of common stock upon vesting of restricted stock units	1,062,120	1	(486)	—	—	(485)
Issuance of common stock under employee stock purchase plan	54,296	—	138	—	—	138
Stock-based compensation expense	—	—	6,951	—	—	6,951
Other comprehensive loss	—	—	—	(115)	—	(115)
Net loss	—	—	—	—	(34,272)	(34,272)
Balance—March 31, 2025	85,579,475	85	809,373	118	(398,492)	411,084
Issuance of common stock upon vesting of restricted stock units	177,600	1	(1)	—	—	—
Repurchase of common stock	(4,619,597)	(5)	(14,088)	—	—	(14,093)
Stock-based compensation expense	—	—	4,667	—	—	4,667
Other comprehensive loss	—	—	—	(81)	—	(81)
Net loss	—	—	—	—	(37,161)	(37,161)
Balance—June 30, 2025	81,137,478	81	799,951	37	(435,653)	364,416
Issuance of common stock under employee stock purchase plan	26,138	—	63	—	—	63
Issuance of common stock for exercise of stock options	17,375	—	58	—	—	58
Repurchase of common stock	(3,054,195)	(3)	(11,423)	—	—	(11,426)
Stock-based compensation expense	—	—	4,517	—	—	4,517
Other comprehensive loss	—	—	—	201	—	201
Net loss	—	—	—	—	(42,049)	(42,049)
Balance—September 30, 2025	78,126,796	$78	$793,166	$238	$(477,702)	$315,780

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.